Workflow
Medtronic(MDT)
icon
Search documents
Medtronic receives FDA approval for smallest-diameter, lumenless defibrillation lead, the OmniaSecure™ lead and announces investigational clinical study results
Prnewswire· 2025-04-25 21:45
Core Insights - Medtronic has received FDA approval for the OmniaSecure™ defibrillation lead, which is designed for precise placement in the right ventricle and is the world's smallest defibrillation lead at 4.7 French (1.6mm) [1][5] - The OmniaSecure lead is built on the SelectSecure™ Model 3830 pacing lead and aims to treat life-threatening ventricular tachyarrhythmias and bradyarrhythmias [1][3] - Investigational studies presented at Heart Rhythm 2025 show a 100% defibrillation success rate when the lead is implanted in the left bundle branch (LBB) area, indicating potential for physiologic pacing [2][6] Company Overview - Medtronic is a global leader in healthcare technology, headquartered in Galway, Ireland, with a mission to alleviate pain, restore health, and extend life [10] - The company employs over 95,000 people across more than 150 countries and offers a wide range of medical technologies and therapies [10] Product Details - The OmniaSecure lead connects to an implantable defibrillator and is indicated for use in adults and adolescent patients aged 12 and up, including those with smaller anatomies [1] - The lead's design minimizes complications associated with larger-diameter leads, such as venous occlusion and tricuspid valve regurgitation [4][5] - The LEADR LBBAP study, which is a global, prospective, non-randomized trial, has enrolled approximately 300 patients across 24 sites in 11 countries [9]
Medtronic (MDT) Rises But Trails Market: What Investors Should Know
ZACKS· 2025-04-23 22:55
Company Performance - Medtronic's stock closed at $83.75, reflecting a +0.46% change, which underperformed compared to the S&P 500's gain of 1.67% [1] - Over the past month, Medtronic shares have decreased by 5.89%, which is less than the Medical sector's decline of 9.34% and the S&P 500's drop of 6.57% [1] Earnings Expectations - Medtronic is set to release its earnings report on May 21, 2025, with an expected EPS of $1.58, representing an 8.22% increase from the same quarter last year [2] - Revenue is forecasted to be $8.81 billion, indicating a growth of 2.57% compared to the prior year [2] Annual Estimates - For the annual period, the Zacks Consensus Estimates predict earnings of $5.46 per share and revenue of $33.48 billion, reflecting increases of +5% and +3.44% respectively from the previous year [3] Analyst Sentiment - Changes in analyst estimates are crucial as they often indicate the company's business health and profitability outlook [3] - The Zacks Rank system, which incorporates these estimate changes, currently ranks Medtronic at 3 (Hold) [5] Valuation Metrics - Medtronic's Forward P/E ratio stands at 15.28, slightly above the industry's Forward P/E of 15.18 [5] - The company has a PEG ratio of 2.1, compared to the Medical - Products industry's average PEG ratio of 2.07 [6] Industry Context - The Medical - Products industry, part of the Medical sector, has a Zacks Industry Rank of 184, placing it in the bottom 26% of over 250 industries [6] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks [7]
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting
Newsfilter· 2025-04-23 13:00
Core Insights - Orchestra BioMed Holdings, Inc. announced an industry-sponsored satellite symposium at the Heart Rhythm Society 2025 Annual Meeting to discuss advancements in its atrioventricular interval modulation (AVIM) therapy program [1][4] - The FDA granted Breakthrough Device Designation to AVIM therapy for treating hypertension in patients with increased cardiovascular risk, highlighting the unmet need in this patient population [2][4] - The BACKBEAT global pivotal study is currently enrolling patients to evaluate the efficacy of AVIM therapy in managing uncontrolled hypertension [2][9] Company Overview - Orchestra BioMed is a biomedical innovation company focused on accelerating high-impact technologies through partnerships with leading medical device companies [7] - The company's lead product candidate is AVIM therapy, aimed at treating hypertension, which is a leading risk factor for death globally [7] - Orchestra BioMed has strategic collaborations with Medtronic for AVIM therapy and Terumo for the Virtue Sirolimus AngioInfusion Balloon [7] Symposium Details - The symposium titled "The Future of Cardiac Pacing: Unlocking the Potential of Atrioventricular Interval Modulation (AVIM) Therapy" will take place on April 25, 2025, at the Hilton San Diego Bayfront Hotel [3] - Presentations will cover clinical results from studies demonstrating AVIM therapy's effectiveness in reducing blood pressure and improving cardiac function [4][5] - Key presentations will include topics on the unmet hypertension need, AVIM therapy's impact on hypertension, and the rationale behind the BACKBEAT study [5][6] Clinical Evidence - AVIM therapy has shown promising results in pilot studies, with reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure and 12.3 mmHg in office systolic blood pressure at six months compared to control patients [9] - The BACKBEAT study aims to further evaluate the safety and efficacy of AVIM therapy in patients with uncontrolled hypertension despite anti-hypertensive medication [9]
Medtronic: Time To Buy This Dividend Aristocrat Bargain
Seeking Alpha· 2025-04-23 07:23
Core Insights - The article discusses the author's journey in dividend growth investing and the establishment of a blog that documents this journey towards financial independence [1]. Group 1 - The author has been investing since September 2017 and has a long-standing interest in dividend investing since 2009 [1]. - The blog "Kody's Dividends" serves as a platform for sharing insights on dividend growth stocks and growth stocks [1]. - The author expresses gratitude for the blog's role in connecting with the Seeking Alpha community as an analyst [1].
Medtronic: A Dividend Aristocrat With Stability and Innovation
MarketBeat· 2025-04-22 14:09
Medtronic TodayMDTMedtronic$82.80 +1.00 (+1.22%) 52-Week Range$75.96▼$96.25Dividend Yield3.38%P/E Ratio25.17Price Target$96.14Add to WatchlistInvestors increasingly seek stable and resilient investments in today's volatile and economically uncertain market. Consequently, it is crucial to identify companies with strong fundamentals, defensive strategies, and dependable shareholder returns. Medtronic plc NYSE: MDT, a leading global healthcare technology company, stands out as a compelling option. It offers a ...
Medtronic: One Of The Best Times To Buy
Seeking Alpha· 2025-04-21 14:30
iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity for sustainable portfolio income , diversification , and inflation hedging . Get started with a Free Two-Week Trial and take a look at our top ideas across our exclusive income-focused portfolios.It’s good to keep a cool head amidst market volatility. While the first reaction may be to hit the sell button, those with a long-term horizon may want to pu ...
New Simplera Sync™ sensor for the MiniMed™ 780G System now FDA approved
Prnewswire· 2025-04-18 23:00
Core Insights - Medtronic has received FDA approval for the Simplera Sync™ sensor, enhancing the MiniMed™ 780G system's capabilities in the U.S. market [1][3] - The Simplera Sync™ sensor is a disposable, all-in-one device that eliminates the need for fingersticks and simplifies the insertion process, providing greater flexibility for users [2][6] - The MiniMed™ 780G system features an adaptive algorithm that adjusts glucose levels every 5 minutes, utilizing Meal Detection™ technology to optimize insulin delivery [2][3] Product Features - The Simplera Sync™ sensor is designed to work seamlessly with the MiniMed™ 780G system, which can now utilize both the Guardian™ 4 sensor and the new Simplera Sync™ sensor [1][3] - The system allows for flexible glucose targets as low as 100 mg/dL and has shown real-world data indicating users achieve over 70% time in range when using optimal settings [2][6] - The MiniMed™ 780G system is the only one that can be paired with an infusion set lasting up to 7 days, significantly reducing the frequency of injections [2][6] Company Commitment - Medtronic is dedicated to innovating diabetes management technologies to improve the quality of life for individuals living with diabetes [3][4] - The company plans a limited launch of the Simplera Sync™ sensor in the U.S. in fall 2025, further expanding its CGM options [3][4] - Medtronic has a long history of pioneering diabetes technology and aims to continue leading in this field through advanced sensors and intelligent dosing systems [4][5]
Why Medtronic Stock Marched Higher on Monday
The Motley Fool· 2025-03-31 22:11
Medtronic (MDT 2.62%) stock was a fairly hot item as the trading week kicked off, with investors pushing the shares up by almost 3% in value. They liked the medical device specialist's latest piece of news about one of its products, and reacted accordingly. The stock's gain easily topped that of the S&P 500 (^GSPC 0.55%), which closed the day up 0.6%. A viable alternative to surgery More encouragingly, those using Medtronic's device demonstrated superior valve performance across the five- year period. Medtr ...
Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update
Newsfilter· 2025-03-31 20:21
NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can estab ...
Prediction: Buying Medtronic Today Will Set You Up for Life
The Motley Fool· 2025-03-28 13:15
Healthcare can be a complex sector, and it is one that I long ago decided to outsource to the industry professionals who run closed-end fund Blackrock Health Sciences Trust. But I couldn't resist dipping my toe into the sector when I saw the historically high yield on offer from Medtronic (MDT -0.21%), one of the largest and most diversified medical device makers.Here's why this is the one healthcare stock I own and why I think it will help set me up for life -- and may do the same for you too if you buy it ...